NCT05681780 2026-03-31
Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Recruiting
H. Lee Moffitt Cancer Center and Research Institute
Essen Biotech
Hadassah Medical Organization
Vall d'Hebron Institute of Oncology
Essen Biotech